Prognosis
Pfizer Keeps 2022 Covid Pill, Vaccine Sales Outlook Unchanged
- Quarterly Covid shot sales beat views, while pill sales miss
- Paxlovid study in immune-compromised patients planned
Pfizer headquarters in New York.
Photographer: Stephanie Keith/BloombergThis article is for subscribers only.
Pfizer Inc. kept its outlook for annual sales of its Covid-19 vaccine and treatment, disappointing investors who looked for the products to continue driving growth.
Through mid-April, Pfizer said it has clinched $32 billion in 2022 contracts for the shot, Comirnaty, and $22 billion for its Covid pill, Paxlovid, the same figures it released three months ago. Wall Street analysts had estimated about $34 billion in annual sales from Comirnaty, which the company makes in partnership with BioNTech SE, and $27 billion in Paxlovid sales.